AOD 9604

AOD9604 is redefining how researchers think about fat metabolism.
Emerging research highlights its ability to activate pathways associated with fat breakdown while limiting fat storage—without impacting blood glucose or lean muscle tissue. Preclinical studies have demonstrated measurable reductions in fat mass, and early human research suggests modest improvements in body composition. This highly targeted activity has positioned AOD9604 as an exciting focus in metabolic and lipolysis research.
Known as Anti-Obesity Drug 9604, AOD9604 was developed by isolating the fat-mobilizing segment of human growth hormone—delivering precision where HGH is broad. Rather than triggering widespread hormonal effects, this peptide zeroes in on metabolic efficiency. Think of it as extracting the most relevant insight from growth hormone science and refining it into a focused research tool.
What truly sets AOD9604 apart is its evolution from a clinical research compound to a GRAS-status nutraceutical ingredient. While clinical outcomes have varied, its strong safety profile and unique mechanism have kept it at the forefront of metabolic investigation. Today, AOD9604 offers researchers a rare opportunity: the ability to study fat metabolism with specificity, clarity, and minimal systemic interference.